PO.PS01.12 · 人群科学
前列腺、肺、结直肠和卵巢(PLCO)癌症筛查试验中全氟和多氟烷基物质的血清浓度与嵌合染色体改变
Serum concentrations of per- and polyfluoroalkyl substances and mosaic chromosomal alterations in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
该海报暂无可下载的资料
AACR 官方页面
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
全氟和多氟烷基物质(PFAS)是可在大多数美国成人血清中检测到的持久性有机污染物。某些PFAS是确定的或可能的人类致癌物。人类细胞和动物中的机制研究提示,PFAS可能通过氧化应激或其他通路引起的间接DNA损伤而产生遗传毒性效应;然而,来自人群的证据仍然有限。我们研究了血清PFAS浓度与嵌合染色体改变(mCA)之间的关系,包括男女中的常染色体mCA以及男性中的嵌合性Y染色体丢失(mLOY),将其作为遗传毒性和基因组不稳定性的生物标志物。我们分析了PLCO癌症筛查试验中三项巢式病例对照研究的2,377名男性和696名女性的血源性DNA。mCA的检测采用高密度基因分型阵列强度数据,针对男女的常染色体,以及单独针对Y染色体男性特异性区域的mLOY。测量了四种PFAS的诊断前血清浓度[全氟辛酸(PFOA)、全氟辛烷磺酸(PFOS)、全氟己烷磺酸(PFHxS)、全氟壬酸(PFNA)]。采用研究特异性的多变量logistic回归,我们分别在癌症病例和无癌对照中估计了血清PFAS浓度与任何可检测的常染色体mCA、任何mLOY以及影响≥10%细胞的mLOY(扩展性mLOY)之间关联的比值比(OR)和95%置信区间(CI)。使用随机效应meta分析汇总研究特异性和病例对照特异性的结果。总体而言,7%的男性和8%的女性检出常染色体mCA。男性中,22%有mLOY,其中8.3%为扩展性mLOY。2%的男性同时具有常染色体mCA和mLOY。我们发现血清PFOS浓度与常染色体mCA之间存在提示性正相关(血清浓度每翻倍,汇总连续OR=1.43,95%CI=0.93-2.21;I平方=49%,P异质性=0.08)。男性中,血清PFHxS与mLOY呈边缘性正相关(任何mLOY,汇总连续OR=1.14,95%CI=0.83-1.40;I平方=59%,P异质性=0.03),且在受影响细胞比例较高者中该关联的量级更强(扩展性mLOY;汇总连续OR=1.19,95% CI=0.89-1.59;I平方=58%,P异质性=0.03)。未观察到其他PFAS的关联。总之,在这项大型基于人群的研究中,我们观察到男女中血清PFOS浓度升高与常染色体mCA之间、以及男性中血清PFHxS与mLOY之间存在正相关的提示性证据。作为首个评估PFAS与mCA关系的研究,我们的发现若得到证实,可能为PFAS对基因组维持相关效应提供与癌症发生相关的新见解。
查看英文原文 English abstract
Per- and polyfluoroalkyl substances (PFAS) are persistent organic pollutants detectable in the serum of most U.S. adults. Some PFAS are established or possible human carcinogens. Mechanistic studies in human cells and animals suggest PFAS may have genotoxic effects through indirect DNA damage caused by oxidative stress or other pathways; however, evidence from human populations remains limited. We investigated the relationship between serum PFAS concentrations and mosaic chromosomal alterations (mCAs), including autosomal mCAs among both men and women and mosaic loss of chromosome Y (mLOY) among men, as biomarkers of genotoxicity and genomic instability. We analyzed blood-derived DNA from 2,377 men and 696 women in three nested case-control studies within the PLCO Cancer Screening Trial. mCAs were detected using high-density genotyping array intensity data for the autosomes in men and women and separately in the male-specific region of the Y chromosome for mLOY. Pre-diagnostic serum concentrations of four PFAS [perfluorooctanoate (PFOA), perfluorooctane sulfonate (PFOS), perfluorohexane sulfonate (PFHxS), perfluorononanoate (PFNA)] were measured. Using study-specific multivariable logistic regression, we estimated odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between serum PFAS concentrations and any detectable autosomal mCA, any mLOY, and mLOY affecting ≥10% of cells (expanded mLOY) among cancer cases and cancer-free controls, separately. Study- and case-control-specific results were summarized using random effects meta-analyses. Overall, autosomal mCAs were detected in 7% of men and 8% of women. Among men, 22% had mLOY, including 8.3% with expanded mLOY. 2% of men had both autosomal mCAs and mLOY. We found a suggestive positive association between serum PFOS concentrations and autosomal mCAs (per doubling in serum concentration, summary OR continuous =1.43, 95%CI=0.93-2.21; I-squared=49%, P-heterogeneity=0.08). Among men, serum PFHxS was marginally positively associated with mLOY (any mLOY, summary OR continuous =1.14, 95%CI=0.83-1.40; I-squared=59%, P-tenerogeneity=0.03), and the magnitude of the association was stronger for those with a higher proportion of affected cells (expanded mLOY; summary OR continuous =1.19, 95% CI=0.89-1.59; I-squared=58%, P-tenerogeneity=0.03). No associations were observed for other PFAS. In conclusion, in this large population-based study, we observed suggestive evidence of a positive association between elevated serum PFOS concentrations and autosomal mCAs among men and women, and between serum PFHxS and mLOY among men. As the first study to evaluate PFAS in relation to mCAs, our findings, if confirmed, may provide new insights into PFAS-related effects on genome maintenance that are relevant to cancer development.
利益披露 Disclosure
J. Rhee, None..
C. R. Robbins, None..
V. C. Chang, None..
W. Zhou, None..
M. J. Machiela, None..
J. N. Hofmann, None..
M. P. Purdue, None..
S. I. Berndt, None.